Table 1 Baseline characteristics of MSU crystal exposed and propensity score matched unexposed individuals
MSU crystals | No crystals | |
|---|---|---|
All | 317 (100.0) | 317 (100.0) |
Male | 277 (87.4) | 275 (86.8) |
Female | 40 (12.6) | 42 (13.2) |
Age | 61 (50–74) | 62 (50–74) |
History of | ||
Ischemic heart disease | 77 (24.3) | 74 (23.3) |
Heart failure | 48 (15.1) | 45 (14.2) |
Atrial fibrillation | 54 (17.0) | 54 (17.0) |
Stroke | 38 (12.0) | 34 (10.7) |
Diabetes mellitus | 48 (15.1) | 40 (12.6) |
Hypertension | 109 (34.4) | 100 (31.5) |
COPD | 33 (10.4) | 30 (9.5) |
Charlson comorbidity index | ||
0 | 147 (46.4) | 152 (47.9) |
1 | 62 (19.6) | 62 (19.6) |
2 | 39 (12.3) | 41 (12.9) |
≥3 | 69 (21.8) | 62 (19.6) |
Current drug use (baseline) | ||
Urate-lowering drugs | 49 (15.5) | 46 (14.5) |
Diabetes drugs (ever use) | 41 (12.9) | 33 (10.4) |
Vitamin K antagonists | 36 (11.4) | 34 (10.7) |
ADP-receptor inhibitor | 8 (2.5) | 6 (1.9) |
Low-dose ASA | 64 (20.2) | 56 (17.7) |
Dipyridamole | 11 (3.5) | 11 (3.5) |
Digitalis | 28 (8.8) | 29 (9.1) |
Nitrates | 15 (4.7) | 15 (4.7) |
Thiazide diuretics | 27 (8.5) | 28 (8.8) |
Loop diuretics | 86 (27.1) | 85 (26.8) |
Aldosterone antagonists | 15 (4.7) | 14 (4.4) |
Beta blockers | 61 (19.2) | 60 (18.9) |
Calcium antagonists | 45 (14.2) | 46 (14.5) |
RAS blockers | 104 (32.8) | 101 (31.9) |
Statins | 64 (20.2) | 56 (17.7) |
COPD drugs | 33 (10.4) | 32 (10.1) |
Systemic corticosteroids | 56 (17.7) | 56 (17.7) |
NSAIDs | 166 (52.4) | 161 (50.8) |
Blood measurements (baseline) | ||
Urate level | 0.53 (0.46–0.61) | 0.43 (0.38–0.50) |
Urate level <0.30 mmol/l | 0 (0.0) | 0 (0.0) |
Urate level 0.30–0.36 mmol/l | 7 (2.2) | 28 (8.8) |
Urate level 0.37–0.42 mmol/l | 43 (13.6) | 129 (40.7) |
Urate level 0.43–0.48 mmol/l | 72 (22.7) | 65 (20.5) |
Urate level >0.48 mmol/l | 195 (61.5) | 95 (30.0) |
eGFR | 68 (51–83) | 70 (53–81) |
High HbA1c (>6.5 %) | 36 (11.4) | 26 (8.2) |
High total cholesterol (>5 mmol/l) | 64 (20.2) | 67 (21.1) |
Proteinuria | 43 (13.6) | 38 (12.0) |